MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.070
-0.010
-0.93%
Opening 10:13 07/16 EDT
OPEN
1.090
PREV CLOSE
1.080
HIGH
1.090
LOW
1.050
VOLUME
67.82K
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
0.7014
MARKET CAP
86.42M
P/E (TTM)
-1.5336
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACRX stock price target is 5.80 with a high estimate of 9.00 and a low estimate of 1.000.

EPS

ACRX News

More
Atlas Technical Consultants Sees Prelim. Q2 Sales $111M-$113M vs $109.25M Est.; Sees FY19 Sales $453M-$468M vs $460.31M Est.
Benzinga · 2d ago
AcelRx: Clever Solution To Painful Problem
Seeking Alpha - Article · 06/26 21:26
Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents · 06/23 02:11
La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.
Benzinga · 06/22 16:14
La Jolla Pharma makes unsolicited bid for Tetraphase Pharma
Seeking Alpha - Article · 06/22 10:33
Trade Alert: The Independent Chairman Of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Adrian Adams, Has Just Spent US$129k Buying 133% More Shares
Simply Wall St. · 06/17 11:33
Melinta inks agreement for Tetraphase buy
Seeking Alpha - Article · 06/09 20:25
Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT
Thomson Reuters StreetEvents · 06/08 19:45

Industry

Biotechnology & Medical Research
-1.12%
Pharmaceuticals & Medical Research
-0.96%

Hot Stocks

Symbol
Price
%Change

About ACRX

AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.
More

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.